Top 10 failed drug development programs by 2020

Affected by the new crown outbreak, the world is paying close attention to the biopharmaceutical sector this year, which is more evident in this year's A-share market performance.
While the focus has been on the development of new coronary pneumonia vaccines and other treatment options, there are still some other changes to be noted by the international pharmaceutical giants in 2020, particularly in the development pipeline for non-sudden diseases.
will help you sort out the research and development pipeline that will be abandoned by pharmaceutical companies in 2020.
, some of the abandoned research and development pipelines will detail the reasons in the company announcement, and some will only be found to have been secretly abandoned after carefully combing through the changes in earnings reports.
: UBX0101 Unity Biotechnology, an anti-aging research start-up founded by Amazon founder Jeff Bezos and PayPal paypal co-founder Peter Thiel, raised $85 million in an 2018 IPO.
anti-apoptosis protein inhibitor UBX0101 is one of Unity Biotechnology's main products, and Phase I clinical trial data released last June show positive results in the treatment of severe knee osteoarthritis (OA).
data, updated in August, showed very depressing results.
12-week follow-up showed no significant statistical difference between any UBX0101 group and placebo.
more than half of the company's share price after the news, prompting restructuring and layoffs.
GlaxoSmithKline: GSK3772847 GSK acquired the rights to GSK3772847 from Johnson and Johnson in 2016 in a deal valued at $230 million, primarily with leukocyte mesotin-33 (IL-33) antagonists that may bind to ST2 subjects to treat most severe asthma.
but in October this year, GSK decided to end further development of the GSK3772847 project after seeing bleak clinical data on Sanofi/Regeneration's same functional target antagonists.
Even so, respiratory candidate drug pipelines have been a key area of GSK, including the now-approved Phase III clinical drugs Nucala and Trelegy, as well as the Phase I study of IL-5 antagonist GSK351294 and the PI4K inhibitor GSK3923868 for the treatment of the worsening of viral chronic obstructive pulmonary disease, which has recently entered phase I development.
Takeda: When SHP647 decided to buy Shire for $62 billion in 2018, one of the European Commission's rules for the acquisition was to spin off Shire's inflammatory enteritis candidate drug, SHP647, which is being evaluated for the treatment of ulcerative colitis or Crohn's disease.
because it is largely aimed at the same patient group, Takeda Pharmaceuticals already has approved Entervio, which will raise questions about competition in the market.
But in 2020, the committee waived Takeda's request to sell SHP647 and certain related rights because of the new crown pandemic, which largely halted trials in March, and Takeda was forced to halt further development because it could not find a new buyer.
the drug was originally developed by Pfizer and licensed to Shire in 2016.
monoclonal antibodies targeting MAdCAM-1, which play a key role in chronic gastrointestinal inflammation, have reached clinical stage II in ulcerative colitis and Crohn's disease, and have obtained the FDA's orphan drug name in childhood ulcerative colitis.
Johnson and Johnson :P imodivir Pimodivir, a flu-treating drug, acquired a global development interest in Pimodivir from Boston-based biopharmaceutical company vertex pharmaceuticals in 2014.
the drug completed a clinical phase IIb study in June 2017 for the treatment of adult patients with seasonal influenza A, and the results showed that Pimodivir monodrive drugs significantly reduced viral load in patients for up to 7 days compared to the placebo group.
same time, Pimodivir and Oseltamivir can reduce the patient's viral load to a lower level without serious adverse reactions.
Pimodivir was approved by the FDA in March 2017 and launched a Clinical Phase III study in the second half of 2017.
but in September this year, interim data from Pimodivir's latest trial showed that when combined with current standards of care, it was unlikely to provide additional benefits when treated with separate standards of care for hospitalized patients with influenza A.
the need for drug use was denied, clinical plans for the trial were cancelled, as was the parallel Phase III trial for outpatient influenza A patients.
Sanofi/Regeneron: SAR440340 /REGN3500 SAR440340, also known as REGN3500, is an all-human monoclonal antibody that inhibits IL-33 and is used to treat moderate to severe asthma.
SAR440340 was developed using veloc Enmunity, a proprietary Technology ® regenerative, which produces optimized all-human antibodies.
last year, the drug's Phase II study reached its primary clinical endpoint for asthma treatment, but it performed worse than the current heavy-weight product Dupixent and had little prospect of combining it with approved drugs.
Sanofi and regeneratives have been testing asthma, specific dermatitis and chronic obstructive pulmonary disease in patients in the group to assess the role of inhibiting IL-33 protein in these patients.
special dermatitis has now been removed from the candidate adaptation, Sanofi did not elaborate on the move.
said only that trials had been suspended due to a lack of technology.
: ASP8374 In 2018, Japan-based Astellas paid $405 million for longtime biotech partner Potenza Therapeutics and its small but promising immuno-oncology drug.
these next-generation cancer drugs include anti-TIGIT therapy, ASP8374 / PTZ-201, which can be used as an antibody immuno checkpoint inhibitor in Phase I clinical studies.
but in late October, Astellas secretly eliminated PTZ-201 with a financial update.
Pfizer :P F-05221304 PF-05221304 is a powerful, selective and reversible dual ACC 1/2 inhibitor (ACCi) designed to have a symmetrical distribution in the liver.
This unsympathetic distribution enables it to effectively inhibit liver acetyl coenzyme a carboxylase to normalize new fats in the liver in patients with non-alcoholic fatty hepatitis (NASH) while minimizing systemic new fat suppression.
PF-05221304 was included in the FAST Track by the FDA.
But in late October, Pfizer removed its development budget for the drug in its earnings report, and the mid-stage PF-05221304 is no longer in the pipeline and is classified as a discontinued project.
Pfizer did not provide a reason to stop monotherapy, but the drug remained active in trials of the combination drug.
this isn't the first time Pfizer has given up NASH-type drugs.
early 2018, the company abandoned a Phase I clinical trial drug, PF-06427878, that is expected to inhibit diamide glycolyceride transferase 2 (DGAT2).
, Pfizer also has several other medium-term research candidates for fatty liver disease, including PF-06835919, a ketone glycosterase (KHK) inhibitor, and PF-06865571, a DGAT2 inhibitor, a successor to the obsolete PF-06427878.
: Balovaptan Balovaptan (aka RG7314) is a drug that selectively inhibits vasopressin-1A receptors and was approved by the FDA in 2018 as a breakthrough therapy for the treatment of autism.
But in this year's quarterly report, Roche announced the termination of two Phase III clinical drugs, including Balovaptan, but the exact cause Roche did not disclose, the company's official website also does not have new autism drugs related to Phase III clinical information.
that Balovaptan's termination may have been caused by Roche evaluating its Phase II clinical results and concluding that there was not enough validity data to support the continuation of Phase III clinical trials.
, the only clinical drug for autism core disorder to enter Phase III was terminated.
Aurinia Pharmaceuticals: Voclosporin Voclosporin stabilizes podocyte by inhibiting the expression of calcium-adjusted neurophosphatase (CN), blocking the expression of IL-2 and T-cell-mediated immune response, and in July this year, the FDA accepted a new drug application for voclosporin's treatment of lupus nephritis (LN) and granted priority review.
, the FDA had previously granted fast-track eligibility for voclosporin treatment for LN.
in November, however, a clinical trial of voclosporin in the field of dry eye disease failed, failing to beat the placebo group in the Phase II/III study to help patients produce more tears.
Ausinia decided to end its program to treat dry eyes at voclosporin, and the only hope now is for the development of lupus nephritis.
GlaxoSmithKline: HVTN 702 HVTN 702 is an improved AIDS vaccine based on RV144, in RV In 144 trials, a combined vaccine consisting of the ALVAC-HIV (vector of canary pox virus) vaccine and the virus surface protein gp120 was shown to be able to protect against HIV intrusion through a "two-pronged effort".
, the ALVAC-HIV vaccine was developed by Sanofi and the gp120 protein sub-base vaccine was developed by GlaxoSmithKline.
trial of HVTN 702 began in 2016 and followed 5,400 sexually active people aged 18-35 in South Africa for 18 months.
participants received six injections in six months, available as a vaccine or placebo.
the end of clinical trials in February 2020, the National Institutes of Health announced, based on trial data, that it would stop clinical trials of the HIV vaccine HVTN 702.
, although no safety risks were found during the trial, the Independent Data and Safety Monitoring Committee found that the vaccine did not prevent the spread of HIV.
source: The top 10 R and D programs to laid rest in 2020